What is tubal embryo transfer?
Tubal embryo transfer (TET) is a part of the process of the Assisted reproductive process (ART), which helps to implantation of the created embryo in a laboratory set-up through the IVF process is transferred into the fallopian tube of the mother/gestational carrier for further growth of the embryo.
TET process description
TET is a standard process of IVF. In the IVF lab, the collected sperm and egg are mixed for fertilization. TET can also apply in the ICSI process, where male factor infertility is also associated. The primary requirement of the TET is healthy fallopian tubes, where the embryo is transferred for further growth and a successful outcome comes after pregnancy. TET is a microsurgical intervention performed under the laparoscopic procedure, which provides a safe and effective outcome. In the tubal embryo transfer system, usually, a two-day-old embryo, which is under the cleavage stage of the embryo formation stage transferred to the fallopian tube through laparoscopic placement.
Advantages of TET
The advantage of this process is the quality of the embryo can be assessed by the embryologist before embryo transfer. In this process, the scope of high-quality embryo transfer possibility is higher due to the quality assessment process.
The procedure of Tubal embryo transfer is usually completed within 30 minutes with quick recovery. In this process need not take complete bed rest after embryo transfer. In the Tubal embryo transfer process, the patient gets a little more recovery period after the retrieval procedure, which is advantageous that patients who have followed Gamete intrafallopian transfer (GIFT) and Zygote Intrafallopian Transfer (ZIFT). GIFT and ZIFT are also other types of embryo transfer processed followed in ART.
Research conducted from 1989 to 1990 had been revealed its result in the Journal of Formosan Medical Association to evaluate the efficacy of TET for infertility treatment. This research result reported that GIFT has provided unsatisfactory results in the case of male factor infertility. In this study, 80 infertile couples participated. Among them, 35 candidates had male factor and 45 couples had female factor infertility issues.
Both of these types of couples had undergone TET to investigate its efficacy. gonadotropin-releasing hormone agonist or human menopausal gonadotropins was the drug of choice for ovulation stimulation. Among eight study participants, ovum retrieval was possible in seventy-three patients, and successful fertilization after insemination occurred in sixty-four of them This is followed by TET, and the process is followed with one-grade III-V embryos. The pregnancy outcome is possible in 35 patients from the 55 cases of TET. Among the male infertility patients, ovulation retrieval was possible in thirty-two, and twenty-four achieved fertilization. This result is 69% had provided a 69% higher pregnancy compared with other groups. The researchers of this investigational study concluded that TET is a valuable ART treatment applicable for non-tubal factor infertility; specifically infertile couples with male factor infertility.
Ravi Sharma is a self-motivated, successful entrepreneur and has a solid experience in the fertility segment. and he is the director at ARTbaby Global (ARThealthcare). He is a pharmacy graduate with post-graduation in business administration and has 14 years of rich experience in the field of infertility segment. He loves to write about IVF, Surrogacy, and other ART (assisted reproductive technology) news, issues, and updates. He is a Pharmacy graduate (B. Pharm) and M.B.A (marketing).
His most recent success includes the successful launch of the medical tourism company, ARTbaby, which offers treatment options for infertility, egg donation, and surrogacy. He likes spending time with his family and writing about various aspects of IVF surrogacy and donating eggs.